• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
Ryan_O'Quinn
Ryan P. O'Quinn, Ph.D.
Partner
More
vCard
  • 1875 Explorer Street
  • Suite 800
  • Reston, VA 20190-6023
+1 571 203 2426
ryan.o'quinn@finnegan.com ryan.o'quinn@finnegan.com

Ryan P. O'Quinn, Ph.D.

Partner

  • +1 571 203 2426 +1 571 203 2426
  • ryan.o'quinn@finnegan.com ryan.o'quinn@finnegan.com
  • 1875 Explorer Street
  • Suite 800
  • Reston, VA 20190-6023
  • vCard
Ryan_O'Quinn

Ryan O'Quinn, Ph.D., maintains a versatile practice focusing on U.S. district court patent litigation, post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), patent prosecution, and portfolio management and counseling. 

Ryan's practice covers a range of technologies, including pharmaceuticals, biotechnology, immunotherapy, medical devices, computer software, business methods, vending technologies, and mechanical systems. He has litigation and counseling experience in small molecule drugs, biologics, and nucleic acid compositions.

Prior to joining Finnegan, Ryan conducted doctoral and undergraduate research in cellular and molecular biology and biomedical engineering. His research, including work at the National Institutes of Health (NIH) and the Marine Biological Laboratory at Woods Hole, focused on advanced microscopy techniques and molecular mechanisms regulating cell division. Ryan previously served as an adjunct professor at George Washington University Law School in the Scholarly Writing Program, where he supervised student members of the Federal Circuit Bar Journal. He has participated as a panel advisor during the Pitch Rounds competition of the Southeast BIO (SEBIO) Annual Life Sciences Venture Capital Conference. Ryan also served as an advisor to the Southeast Life Sciences (SLSA) ADVANSE Virtual Pitch Rounds competition which featured early-stage life sciences companies developing solutions related to COVID-19.

Ryan has successfully represented, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veterans Claims. He also serves as a member of the Friends Board of the Legal Services of Northern Virginia.

Et Cetera

  • Capital Pro Bono High Honor Roll, 2018.
  • Member of the firm's Associate Advisory Committee, 2013-2015.
  • Former chief executive editor of the Duke Law & Technology Review, 2011-2012.
  • Former senior lead editor of the Alaska Law Review, 2011-2012.

Experience

The Hillman Group, Inc. v. KeyMe, LLC
Representing Hillman in a patent infringement suit against a competitor involving key duplication technology.

2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap

KeyMe, LLC v. The Hillman Group, Inc.
Representing Hillman in a patent infringement suit against a competitor involving key duplication technology.

1:19-cv-01539, D. Del., Judge Stark

 AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc.
Representing AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against Zydus on its Farxiga® pharmaceutical drug product.

1:18-cv-00664, D. Del., Judge Andrews

Shire ViroPharma Inc. v. CSL Behring LLC
Representing defendant CSL Behring in patent litigation concerning its biologic Haegarda® for the prophylactic prevention of hereditary angioedema.

1:17-cv-00414, D. Del., Judges Goldberg, Thynge

AstraZeneca LP v. SigmaPharm Laboratories
Representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.

1:15-cv-01000, D. Del., Judge Andrews

The Hillman Group, Inc. v. Minute Key, Inc.
Represented Hillman in a patent-related Lanham Act and state law false advertising action against a competitor. Following trial, the jury returned a verdict in favor of Hillman.

1:13-cv-00707, S.D. Ohio, Judge Dlott

Eli Lilly and Company v. Zenith Goldline Pharmaceuticals

Represented Eli Lilly in a district court contempt proceeding enforcing a permanent injunction covering its Zyprexa® drug product.

1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa

The Hillman Group, Inc. v. KeyMe, LLC

Representing Hillman in a patent infringement suit against a competitor involving key duplication technology.

2:19-cv-00209; 2:20-cv-00070, E.D. Tex., Judge Gilstrap

KeyMe, LLC v. The Hillman Group, Inc.

Representing Hillman in a patent infringement suit against a competitor involving key duplication technology.

1:19-cv-01539, D. Del., Judge Stark

 AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc.

Representing AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against Zydus on its Farxiga® pharmaceutical drug product.

1:18-cv-00664, D. Del., Judge Andrews

Shire ViroPharma Inc. v. CSL Behring LLC

Representing CSL Behring in a patent infringement suit against a competitor involving C1-INH biologic drugs for use in treating hereditary angioedema (HAE).

1:17-cv-00414, D. Del., Judges Goldberg, Thynge

AstraZeneca LP v. SigmaPharm Laboratories

Representing AstraZeneca in in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.

1:15-cv-01000, D. Del., Judge Andrews

The Hillman Group, Inc. v. Minute Key, Inc.

Represented Hillman in a patent-related Lanham Act and state law false advertising action against a competitor. Following trial, the jury returned a verdict in favor of Hillman.

1:13-cv-00707, S.D. Ohio, Judge Dlott

9 more

Insights

Webinar

Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity

November 17, 2020

Webinar

Conference

2020 AdvanSE Life Sciences Virtual Conference 2020 AdvanSE Life Sciences Virtual Conference

November 9-13, 2020

Virtual

Webinar

Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation

Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation

October 16, 2019

Webinar

Articles

FDA Commissioner’s Statement on Plans for the Orange Book FDA Commissioner’s Statement on Plans for the Orange Book

March 9, 2019

FDA Flash! Blog

IP FDA Blog

FDA Commissioner Statement about the Orange Book FDA Commissioner Statement about the Orange Book

February 7, 2019

Articles

Could the 'Dance' Already Be Over? ACA Repeal and Biosimilars Could the 'Dance' Already Be Over? ACA Repeal and Biosimilars

February 17, 2017

BNA's Life Sciences Law & Industry Report
4 more

News

Press Release

Finnegan Elevates Six Attorneys to Partner Finnegan Elevates Six Attorneys to Partner

January 4, 2021

Announcement

Best Lawyers Recognizes 21 Finnegan Attorneys Best Lawyers Recognizes 21 Finnegan Attorneys

August 28, 2020

Press Release

62 Finnegan Attorneys Named to 2018 Capital Pro Bono Honor Roll 62 Finnegan Attorneys Named to 2018 Capital Pro Bono Honor Roll

April 5, 2019

Professional Activities

  • American Bar Association
  • American Intellectual Property Law Association
  • American Society for Cell Biology
Admissions and Education

Admissions

  • District of Columbia
  • Virginia
  • U.S. District Court, E.D. Virginia
  • U.S. Court of Appeals, Veterans Claims
  • U.S. Patent and Trademark Office

Education

Duke University School of Law
J.D., 2012
University of North Carolina, Chapel Hill
Ph.D., Biology, 2009
North Carolina State University
B.S., Biological Engineering, magna cum laude, 2004
North Carolina State University
B.A., History, magna cum laude, 2004

Ryan's Practices

Patent Litigation
Appeals
Arbitration and Other ADR
Branded Hatch-Waxman (ANDA)
Patent Trial
Pre-Trial Strategy
Settlement
Patent Office Examinations
Appeals to the PTAB
Prosecution
Patent Portfolio Management, Monetization, and Transactions
Due Diligence
Licensing, Pooling, and Other Transactions
Opinions and Counseling
Portfolio Management
Post-Grant Proceedings
Interferences

Ryan's Industries

Chemical, Industrial, and Materials
Manufacturing
Hospitality, Gaming, and Leisure
Food and Beverage
Life Sciences
Biologics
Biotechnology
Medical Device and Diagnostics
Pharmaceutical

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP